In a previous study, the inhibition of thrombopoietin or IL-6 prevented the development of thrombocytosis in mice and significantly enhanced the therapeutic efficacy of paclitaxel in mouse models of epithelial ovarian cancer [24]. This evidence concerns the gene IL6 and thrombocytosis disease.